Steve Kornblau

List of Publications by Year in descending order

180 papers	9,902 citations	44069 48 h-index	39675 94 g-index
183 all docs	183 docs citations	183 times ranked	13719 citing authors

#	Article	IF	Citations
1	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 2022, 139, 907-921.	1.4	34
2	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia, 2022, 36, 712-722.	7.2	4
3	Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Childrenâ€™s Oncology Group study. Haematologica, 2022, , .	3.5	7
4	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer Journal, 2022, 12, 43.	6.2	5
5	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	4.1	31
6	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 2801.	12.8	25
7	The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nature Cell Biology, 2022, 24, 872-884.	10.3	25
8	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood, 2021, 137, 1050-1060.	1.4	10
9	The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. Journal of Proteomics, 2021, 233, 104046.	2.4	8
10	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
11	Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clinical Epigenetics, 2021, 13, 21.	4.1	12
12	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	6.2	24
13	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood, 2021, 138, 2383-2395.	1.4	13
14	Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Frontiers in Oncology, 2021, 11, 705627.	2.8	7
15	Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. Oncogene, 2021, 40, 6166-6179.	5.9	7
16	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	1.6	173
17	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071.	12.8	44
18	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NFâ€ÎºB subunit RelA. Proteomics - Clinical Applications, 2021, , 2100072.	1.6	4

#	Article	IF	Citations
19	Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78. Blood, 2021, 138, 3447-3447.	1.4	0
20	Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Review of Proteomics, 2021, 18, 1087-1097.	3.0	0
21	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263.	3.7	7
22	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer Journal, 2020, 10, 61.	6.2	20
23	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924.	7.2	7
24	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
25	The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Science Translational Medicine, 2020, 12, .	12.4	33
26	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	7.2	37
27	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. Expert Review of Proteomics, 2020, 17, 1-10.	3.0	13
28	Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood, 2020, 136, 10-11.	1.4	5
29	Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2020, 136, 7-9.	1.4	5
30	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget, 2020, 11, 2387-2403.	1.8	18
31	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Blood, 2020, 136, 29-31.	1.4	0
32	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood, 2020, 136, 18-20.	1.4	2
33	The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. Blood, 2020, 136, 1-2.	1.4	0
34	Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia. Blood, 2020, 136, 24-24.	1.4	2
35	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood, 2020, 136, 43-45.	1.4	10
36	Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood, 2020, 136, 7-7.	1.4	3

#	Article	IF	Citations
37	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine Â± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	1.4	0
38	Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics - Clinical Applications, 2019, 13, 1800133.	1.6	7
39	LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine, 2019, 44, 126-137.	6.1	14
40	A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. Nature Biomedical Engineering, 2019, 3, 889-901.	22.5	27
41	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood, 2019, 134, 59-73.	1.4	75
42	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	4.6	84
43	Targeting nuclear Î²-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia, 2019, 33, 1373-1386.	7.2	32
44	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
45	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal, 2019, 9, 4.	6.2	57
46	Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair. Oncotarget, 2019, 10, 4679-4690.	1.8	5
47	Antibody Screening. Advances in Experimental Medicine and Biology, 2019, 1188, 149-163.	1.6	1
48	Histone Modification Patterns Using RPPAâ€Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients. Proteomics, 2018, 18, e1700379.	2.2	11
49	Disruption of Wnt/Î²-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 2417-2429.	7.0	65
50	Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Molecular Cancer Research, 2018, 16, 1275-1286.	3.4	16
51	Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Molecular Cancer Research, 2018, 16, 1263-1274.	3.4	12
52	Role of MSC-derived galectin 3 in the AML microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 959-969.	4.1	16
53	Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica, 2018, 103, 810-821.	3.5	33
54	Necrotizing fungal gingivitis in a patient with acute myelogenous leukemia: Visible yet obscure. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2018, 30, 50-54.	0.3	2

#	Article	IF	Citations
55	Mycoplasma contamination of leukemic cell lines alters protein expression determined by reverse phase protein arrays. Cytotechnology, 2018, 70, 1529-1535.	1.6	7
56	Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell, 2018, 34, 499-512.e9.	16.8	209
57	VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Research, 2018, 78, 5940-5948.	0.9	12
58	Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Informatics, 2018, 17, 117693511877108.	1.9	20
59	Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Review of Proteomics, 2018, 15, 613-622.	3.0	3
60	Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular Cancer Therapeutics, 2017, 16, 1133-1144.	4.1	30
61	Metabolic gatekeeper function of B-lymphoid transcription factors. Nature, 2017, 542, 479-483.	27.8	175
62	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology, 2017, 18, 694-704.	14.5	67
63	Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1207-1218.	1.3	24
64	p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia, 2017, 31, 1296-1305.	7.2	87
65	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2017, 18, 1618.	4.1	37
66	Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Frontiers in Immunology, 2017, 8, 1975.	4.8	18
67	Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget, 2017, 8, 83354-83369.	1.8	7
68	Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 64.	17.0	20
69	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	7.2	99
70	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood, 2016, 128, 1260-1269.	1.4	104
71	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	21.4	231
72	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Computational Biology, 2016, 12, e1004890.	3.2	28

#	Article	IF	Citations
73	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget, 2016, 7, 55083-55097.	1.8	31
74	Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFÎºB/IL1Î² signaling network. Oncotarget, 2016, 7, 20054-20067.	1.8	32
75	Preclinical activity of the novel Bâ€cellâ€specific Moloney murine leukemia virus integration site 1 inhibitor PTC â€209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Science, 2015, 106, 1705-1713.	3.9	27
76	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
77	PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood, 2015, 126, 1585-1594.	1.4	26
78	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood, 2015, 126, 2491-2501.	1.4	180
79	Progeny Clustering: A Method to Identify Biological Phenotypes. Scientific Reports, 2015, 5, 12894.	3.3	36
80	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	16.8	265
81	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 2015, 100, 927-934.	3.5	93
82	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports, 2015, 13, 2715-2727.	6.4	118
83	Phosphorylation of GSK3Î±/Î² correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clinical, 2015, 4, 59-68.	4.1	37
84	Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia. Leukemia, 2015, 29, 1218-1221.	7.2	7
85	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell, 2015, 28, 486-499.	16.8	110
86	Loss of TRIM62 Expression Is an Independent Adverse Prognostic Factor in Acute MyeloidÂLeukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 115-127.e15.	0.4	28
87	Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget, 2015, 6, 14970-14981.	1.8	25
88	The Use of â€œOmicsâ€•to Guide the Selection of Targeted Therapy. , 2015, , 27-43.		0
89	STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes and Cancer, 2014, 5, 378-392.	1.9	14
90	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 2226-2235.	7.0	71

#	Article	IF	Citations
91	WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia, 2014, 28, 1171-1174.	7.2	208
92	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	16.8	292
93	BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia, 2014, 28, 1657-1665.	7.2	171
94	Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. Journal of the National Cancer Institute, 2014, 106, djt440.	6.3	75
95	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
96	The protein phosphatase 2A regulatory subunit B55Î± is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1969-1977.	4.1	32
97	Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. , 2014, 86, 383-396.		6
98	hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014, 124, 2382-2382.	1.4	1
99	Transglutaminase 2 expression in acute myeloid leukemia: Association with adhesion molecule expression and leukemic blast motility. Proteomics, 2013, 13, 2216-2224.	2.2	31
100	BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 2013, 12, 2940-2949.	4.1	29
101	Notch activation inhibits AML growth and survival: a potential therapeutic approach. Journal of Experimental Medicine, 2013, 210, 321-337.	8.5	139
102	Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood, 2013, 121, 4166-4174.	1.4	184
103	Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. , 2013, , n/a-n/a.		5
104	Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS ONE, 2013, 8, e78453.	2.5	48
105	BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses. Blood, 2013, 122, 603-603.	1.4	2
106	Phosphorylation Of GSK3Î² Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood, 2013, 122, 2551-2551.	1.4	0
107	Modeling Protein Expression and Protein Signaling Pathways. Journal of the American Statistical Association, 2012, 107, 1372-1384.	3.1	19
108	Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots. Cancer Informatics, 2012, 11, CIN.S9055.	1.9	40

#	Article	IF	Citations
109	PKCÎ´ Regulates Translation Initiation through PKR and eIF2Î± in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leukemia Research and Treatment, 2012, 2012, 1-17.	2.0	8
110	Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Annals of Hematology, 2012, 91, 1861-1870.	1.8	129
111	Network analysis of reverse phase protein expression data: Characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16). Proteomics, 2012, 12, 2084-2093.	2.2	10
112	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34â€positive compartment. Cancer, 2012, 118, 5283-5292.	4.1	36
113	TGF-Î²1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion. Blood, 2012, 120, 3543-3543.	1.4	3
114	Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood, 2012, 120, 534-534.	1.4	0
115	Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1135-1149.	8.5	140
116	Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood, 2011, 118, 5604-5612.	1.4	58
117	Low expression of PP2A regulatory subunit B55Î± is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia, 2011, 25, 1711-1717.	7.2	71
118	Use of Reverse Phase Protein Microarrays to Study Protein Expression in Leukemia: Technical and Methodological Lessons Learned. Methods in Molecular Biology, 2011, 785, 141-155.	0.9	26
119	Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist,. Blood, 2011, 118, 3776-3776.	1.4	5
120	Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Blood, 2011, 118, 66-66.	1.4	5
121	EphrinB1 Activation As a Potential New Treatment Option in AML. Blood, 2011, 118, 5235-5235.	1.4	4
122	Low Expression of the Novel Tumor Suppressor Trim62 Is An Independent Adverse Prognostic Factor for Survival In Acute Myeloid. Blood, 2011, 118, 563-563.	1.4	1
123	Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood, 2010, 116, 4251-4261.	1.4	134
124	Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy. Clinical Cancer Research, 2010, 16, 3721-3733.	7.0	59
125	Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 1865-1874.	7.0	130
126	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	1.4	3

#	Article	IF	Citations
127	Genome-Wide Epigenetic Analysis of Cancer Stem Cells (CSCs) In Acute Myeloid Leukemia.. Blood, 2010, 116, 3640-3640.	1.4	1
128	Variable slope normalization of reverse phase protein arrays. Bioinformatics, 2009, 25, 1384-1389.	4.1	82
129	Functional proteomic profiling of AML predicts response and survival. Blood, 2009, 113, 154-164.	1.4	235
130	Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.. Blood, 2009, 114, 2031-2031.	1.4	3
131	Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia.. Blood, 2009, 114, 402-402.	1.4	1
132	FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.. Blood, 2009, 114, 1588-1588.	1.4	1
133	The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both Allâ€“Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2009, 114, 4143-4143.	1.4	0
134	Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 45-45.	1.4	28
135	Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood, 2008, 112, 759-759.	1.4	5
136	Clonal Abnormalities in MSC Derived from AML Bone Marrows. Blood, 2008, 112, 2428-2428.	1.4	0
137	Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood, 2007, 109, 2999-3006.	1.4	107
138	Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Experimental Hematology, 2007, 35, 842-853.	0.4	10
139	P53 Protein Expression Levels Are Prognostic in AML and Predict for Mutational Status.. Blood, 2007, 110, 2397-2397.	1.4	1
140	Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells.. Blood, 2007, 110, 3472-3472.	1.4	9
141	Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood, 2006, 108, 2358-2365.	1.4	230
142	Studying The Right Cell In Acute Myelogenous Leukemia: Dynamic Changes Of Apoptosis And Signal Transduction Pathway Protein Expression In Chemotherapy Resistant Ex-Vivo Selected â€œSurvivor Cellsâ€• Cell Cycle, 2006, 5, 2769-2777.	2.6	19
143	Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Molecular Cancer Therapeutics, 2006, 5, 2512-2521.	4.1	607
144	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. Blood, 2006, 108, 1966-1966.	1.4	3

#	Article	IF	Citations
145	Cytokine Profiling of Acute Meylogenous Leukemia and Myelodysplasia.. Blood, 2006, 108, 2355-2355.	1.4	0
146	High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins.. Blood, 2006, 108, 107-107.	1.4	5
147	Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia, 2005, 19, 1550-1557.	7.2	15
148	Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s).. Blood, 2005, 106, 1219-1219.	1.4	1
149	Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).. Blood, 2005, 106, 484-484.	1.4	3
150	Survivor Cells Predict Which Patients Will Respond to Therapy with VNP40101M and Ara-C.. Blood, 2004, 104, 2027-2027.	1.4	6
151	Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2004, 104, 2738-2738.	1.4	9
152	Prolonged Administration of Arsenic Trioxide (TrisenoxÂ®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.. Blood, 2004, 104, 4731-4731.	1.4	1
153	Simultaneous Activation of Multiple Signal Transduction Pathways Confers Poor Prognosis in Acute Myelogenous Leukemia.. Blood, 2004, 104, 2992-2992.	1.4	2
154	Melphalan and purine analogâ€“containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 2001, 97, 631-637.	1.4	551
155	Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Research, 2001, 61, 3355-60.	0.9	12
156	Harnessing graftâ€•versusâ€•malignancy: nonâ€•myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	2.5	6
157	BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clinical Cancer Research, 2000, 6, 1401-9.	7.0	50
158	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. Journal of Clinical Oncology, 1999, 17, 284-284.	1.6	135
159	Altered Expression of Retinoblastoma (RB) Protein in Acute Myelogenous Leukemia Does not Result from Methylation of the Rb Promotor. Leukemia and Lymphoma, 1999, 35, 283-288.	1.3	10
160	Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1999, 35, 483-489.	1.3	13
161	Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opinion on Investigational Drugs, 1999, 8, 2027-2057.	4.1	16
162	The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clinical Cancer Research, 1999, 5, 1758-66.	7.0	68

#	Article	IF	Citations
163	Cecaâ€“Cyclophosphamide, Etoposide, Carboplatin and Cytosine Arabinosideâ€“A New Salvage Regimen for Relapsed or Refractory Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1998, 28, 371-375.	1.3	7
164	Characterization of the ETO and AML1â€“ETO proteins involved in the 8;21 translocation in acute myelogenous leukemia. European Journal of Haematology, 1998, 60, 217-225.	2.2	27
165	Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clinical Cancer Research, 1998, 4, 1955-63.	7.0	13
166	Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.. Journal of Clinical Oncology, 1997, 15, 1796-1802.	1.6	88
167	Disseminated Intravascular Coagulation in Adult Acute Lymphoblastic Leukemia: Frequent Complications with Fibrinogen Levels Less than 100 mg/dl. Leukemia and Lymphoma, 1996, 21, 85-92.	1.3	37
168	Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia, 1996, 10, 1563-9.	7.2	60
169	Quantitive Expression of Proliferating Cell Nuclear Antigen by Western Blot (PCNAWB) in Peripheral Blasts Correlates with Remission Induciton in Patients with Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1995, 19, 235-241.	1.3	5
170	Growth-Factor Stimulation Reveals Two Mechanisms of Retinoblastoma Gene Inactivation in Human Myelogenous Leukemia Cells. Leukemia and Lymphoma, 1995, 16, 191-198.	1.3	3
171	Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia, 1995, 9, 1735-41.	7.2	17
172	High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clinical Cancer Research, 1995, 1, 1051-7.	7.0	79
173	Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 1994, 84, 256-61.	1.4	13
174	Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Research, 1994, 54, 242-6.	0.9	33
175	Molecular approaches to the diagnosis and treatment of cancer. Stem Cells, 1993, 11, 129-130.	3.2	1
176	Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia, 1993, 7, 378-83.	7.2	31
177	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1992, 6, 89-95.	1.3	5
178	Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Research, 1992, 52, 4587-90.	0.9	30
179	Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns. , 0, , .		1
180	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfanâ€‰Â±â€‰clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	3